by The global Genitourinary drugs market size was estimated to be around US$ 29.24 billion in 2023. It is projected to reach US$ 32.27 billion by 2032, indicating a CAGR of 1.1% from 2023 to 2032.
Key Takeaways
- North America contributed more than 49% of revenue share in 2022.
- Asia-Pacific is estimated to witness the fastest CAGR between 2023 and 2032.
- By indication, the prostate cancer segment held the largest market share of 28% in 2022.
- By indication, the cervical cancer segment is anticipated to grow at a remarkable CAGR of 2.5% between 2023 and 2032.
- By product, the hormonal therapy segment generated over 38% of revenue share in 2022.
- By product, the gynecological segment is expected to expand at the fastest CAGR over the projected period.
The market research report on the Genitourinary drugs market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Genitourinary drugs products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample: https://www.precedenceresearch.com/sample/3644
Genitourinary Drugs Market Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 29.24 Billion |
| Market Size by 2032 | USD 32.27 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 1.1% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Indication and By Product |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Colorectal Cancer Therapeutics Market Size to Garner USD 18.25 Billion by 2032
The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global Genitourinary drugs market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Genitourinary drugs market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Genitourinary drugs products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the Genitourinary drugs market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on Genitourinary drugs market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Genitourinary drugs market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Recent Developments
- In April 2023, GSK plc reported encouraging results from the EAGLE-2 and EAGLE-3 clinical trials for gepotidacin. The positive outcome in Phase III trials positions gepotidacin as a potential breakthrough, being the first orally administered antibiotic in its class for treating uncomplicated urinary tract infections (uUTI) in female adolescents and adults.
- In March 2023, Pfizer Inc. disclosed its definitive merger agreement with Seagen Inc., a biotechnology firm known for its innovation in cancer medicines and expertise in antibody-drug conjugate (ADC) technology. This strategic collaboration marks a significant development in Pfizer’s pursuit of advancements in cancer treatment and underscores Seagen’s valued position in the field.
Genitourinary Drugs Market Players
- Pfizer Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Novartis AG
- Eli Lilly and Company
- AstraZeneca PLC
- Bayer AG
- Sanofi S.A.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Astellas Pharma Inc.
- Boehringer Ingelheim International GmbH
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Takeda Pharmaceutical Company Limited
Segments Covered in the Report
By Indication
- Prostate Cancer
- Ovarian Cancer
- Bladder Cancer
- Cervical Cancer
- Renal Cancer
- Erectile Dysfunction
- Urinary Tract Infections
- Urinary Incontinence & Overactive Bladder
- Sexually Transmitted Diseases
- Interstitial Cystitis
- Haematuria
- Benign Prostatic Hyperplasia
By Product
- Urologicals
- Hormonal Therapy
- Gynecological
- Anti-infectives
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Genitourinary Drugs Market
5.1. COVID-19 Landscape: Genitourinary Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Genitourinary Drugs Market, By Indication
8.1. Genitourinary Drugs Market Revenue and Volume, by Indication, 2023-2032
8.1.1. Prostate Cancer
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Ovarian Cancer
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Bladder Cancer
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. Cervical Cancer
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
8.1.5. Renal Cancer
8.1.5.1. Market Revenue and Volume Forecast (2020-2032)
8.1.6. Erectile Dysfunction
8.1.6.1. Market Revenue and Volume Forecast (2020-2032)
8.1.7. Urinary Tract Infections
8.1.7.1. Market Revenue and Volume Forecast (2020-2032)
8.1.8. Urinary Incontinence & Overactive Bladder
8.1.8.1. Market Revenue and Volume Forecast (2020-2032)
8.1.9. Sexually Transmitted Diseases
8.1.9.1. Market Revenue and Volume Forecast (2020-2032)
8.1.10. Interstitial Cystitis
8.1.10.1. Market Revenue and Volume Forecast (2020-2032)
8.1.11. Haematuria
8.1.11.1. Market Revenue and Volume Forecast (2020-2032)
8.1.12. Benign Prostatic Hyperplasia
8.1.12.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Genitourinary Drugs Market, By Product
9.1. Genitourinary Drugs Market Revenue and Volume, by Product, 2023-2032
9.1.1. Urologicals
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Hormonal Therapy
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Gynecological
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
9.1.4. Anti-infectives
9.1.4.1. Market Revenue and Volume Forecast (2020-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Genitourinary Drugs Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.1.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.1.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.1.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.2.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.2.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.2.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.2.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.2.6.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.3.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.3.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.3.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.3.6.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.4.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.4.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.4.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.4.6.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.5.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)
10.5.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)
Chapter 11. Company Profiles
11.1. GlaxoSmithKline
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. AstraZeneca
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. CytoSorbents Corporation
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Cardinal Health
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Asahi Kasei
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. ConvaTec
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. CHIESI Farmaceutici
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Smith & Nephew
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
